Michael Gelband’s Yarrow Bioscience YARW Stock Holding History

Michael Gelband’s Portfolio YARW Stock Details YARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-54	Closed	-$68K	–	2639
2021 Q3	$68K	Sell	54 -7	-11%	-$13.6K	﹤0.01%	1948
2021 Q2	$194K	Buy	+61	New	+$241K	﹤0.01%	1996

Other funds holding YARW

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Michael Gelband's YARW Position: Q4 2021 in Review

Michael Gelband sold out of Yarrow Bioscience (YARW) in Q4 2021, closing a stake of 54 shares — an estimated $68K sold.

Michael Gelband first reported a position in YARW in Q2 2021 and held it in 2 quarters. The position peaked at $194K in Q2 2021. 49 funds tracked by Wall St. Rank hold YARW as of Q4 2021.

Michael Gelband reported no remaining Yarrow Bioscience position as of Q4 2021 after selling out during the quarter.
Michael Gelband sold 54 Yarrow Bioscience shares in Q4 2021, an estimated $68K.
Michael Gelband first reported a position in Yarrow Bioscience in Q2 2021 and held it in 2 quarters.
Michael Gelband's Yarrow Bioscience position peaked at $194K in Q2 2021.
49 funds tracked by Wall St. Rank held Yarrow Bioscience as of Q4 2021.

Based on ExodusPoint Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.